Abstract
Objectives This study compares remote neurodegenerative changes caudal to a cervical injury in degenerative cervical myelopathy (DCM) (i.e. non-traumatic) and incomplete traumatic spinal cord injury (tSCI) patients, using MRI-based tissue area measurements and diffusion tensor imaging (DTI).
Methods Eighteen mild to moderate DCM patients with sensory impairments (mean mJOA score: 16.2), 14 incomplete tetraplegic tSCI patients (AIS C&D), and 20 healthy controls were recruited. All participants received DTI and T2*-weighted scans in the lumbosacral enlargement (caudal to injury) and at C2/C3 (rostral to injury). MRI readouts included DTI metrics in the white matter (WM) columns and cross-sectional WM and gray matter area. One-way ANOVA with Tukey post-hoc comparison (p<0.05) was used to assess group differences.
Results In the lumbosacral enlargement, compared to DCM, tSCI patients exhibited decreased fractional anisotropy in the lateral (tSCI vs. DCM, −11.9%, p=0.007) and ventral WM column (−8.0%, p=0.021), and showed trend toward lower values in the dorsal column (−8.9%, p=0.068). At C2/C3, no differences in DTI metrics were observed between DCM and tSCI, but compared to controls, fractional anisotropy was lower in both groups in the dorsal (DCM vs. controls, −7.9%, p=0.024; tSCI vs. controls, −10.0%, p=0.007) and in the lateral column (DCM: −6.2%, p=0.039; tSCI: −13.3%, p<0.001). WM areas were not different between patient groups, but were significantly lower compared to healthy controls both in the lumbosacral enlargement (DCM: −16.9%, p<0.001; tSCI, −10.5%, p=0.043) and at C2/C3 (DCM: −16.0%, p<0.001; tSCI: −18.1%, p<0.001).
Conclusion In conclusion, mild to moderate DCM and incomplete tSCI lead to similar degree of degeneration of the dorsal and lateral columns at C2/C3, but tSCI results in more widespread white matter damage in the lumbosacral enlargement. These remote changes are likely to contribute to the impairment and recovery of the patients. Diffusion MRI is a sensitive tool to assess remote pathological changes in DCM and tSCI patients.
Competing Interest Statement
The Wellcome Trust Centre for Neuroimaging and Max Planck Institute for Human Cognitive and Brain Sciences have an institutional research agreement with and receives support from Siemens Healthcare.
Funding Statement
This study is funded by Wings for Life (WFL-CH-007/14), the International Foundation for Research in Paraplegia (IRP-P158 and IRP-P184), the European Union's Horizon 2020 (grant agreement no. 681094, 'NISCI'), the framework of ERA-NET NEURON (hMRIofSCI no: 32NE30_173678), and the Swiss State Secretariat for Education, Research and Innovation (SERI) (contract number: 15.0137). PF is funded by an SNF Eccellenza Professorial Fellowship grant (PCEFP3_181362/1). MS is funded by Wings for Life (WFL-CH-19/20) and Balgrist-Stiftung 2021. Open access of this publication is supported by the Wellcome Trust (091593/Z/10/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was designed in accordance with the Declaration of Helsinki and was approved by the local ethics committee (Kantonale Ethikkommission Zurich, EK-2010-0271).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact addresses of co-authors Gergely David, gergely.david{at}balgrist.ch, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland, Phone: +41 44 510 7213
Kevin Vallotton, vallottonk{at}gmail.com, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland, Phone: +41 44 510 7214
Markus Hupp, markus.hupp{at}balgrist.ch, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland, Phone: +41 44 510 7213
Armin Curt, armin.curt{at}balgrist.ch, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland, Phone: +41 44 386 3901
Patrick Freund, patrick.freund{at}balgrist.ch, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland, Phone: +41 44 510 7211
Maryam Seif, maryam.seif{at}balgrist.ch, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland, Phone: +41 44 510 7214
Data Availability
The authors certify they have documented all data, methods, and materials used to conduct the research presented. Anonymized data pertaining to the research presented will be made available by request from qualified investigators.